Member Success: Congratulations to Agilent Technologies on the news of your $925M acquisition agreement with BIOVECTRA. #CoBioScience #StrongerTogether #BuildingMomentum #ForgingLifeSciencesFrontier
We are pleased to announce that Agilent has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization (CDMO) based in Canada. BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specialization in oligonucleotides and CRISPR therapeutics by expanding our portfolio of services, adding rapidly growing modalities, and bringing world-class capabilities to support gene editing. Read more about this exciting news: https://bit.ly/4frBAur.